Taken together, our data demonstrate the anti-tumor activity of elacestrant, as a single agent, and/or in combination with inhibitors of the PI3K/mTOR pathway, in models derived from patients who did not benefit from palbociclib treatment in the clinic. This evidence concerns the gene MTOR and neoplasm.